A Parallel Group, Double-Blind, Randomized, Placebo Controlled Phase 3 Trial to Evaluate the Efficacy and Safety of ALD403 Administered Intravenously in Patients With Chronic Migraine

Trial Profile

A Parallel Group, Double-Blind, Randomized, Placebo Controlled Phase 3 Trial to Evaluate the Efficacy and Safety of ALD403 Administered Intravenously in Patients With Chronic Migraine

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 08 Jan 2018

At a glance

  • Drugs Eptinezumab (Primary)
  • Indications Migraine
  • Focus Registrational; Therapeutic Use
  • Acronyms PROMISE 2
  • Sponsors Alder Biopharmaceuticals
  • Most Recent Events

    • 08 Jan 2018 According to an Alder Biopharmaceuticals media release, full safety data will be available at the completion of the study
    • 08 Jan 2018 Primary endpoint has been met. (Change in frequency of migraine days), according to an Alder Biopharmaceuticals media release
    • 08 Jan 2018 Results published in an Alder Biopharmaceuticals Media Release
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top